Lung Biology and Pathophysiology
Herausgeber: Zhao, Yutong
Lung Biology and Pathophysiology
Herausgeber: Zhao, Yutong
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
The lungs are the organ for gas exchange between the body and the external environment. This book contributes to the understanding homeostasis of lung cells in the physiological and pathological conditions critical to the development of novel therapeutics.
Andere Kunden interessierten sich auch für
- Catherine H ScheinConditionally Toxic Proteins129,99 €
- Eric Moody / Phil Skolnick (eds.)Molecular Bases of Anesthesia371,99 €
- Christopher R. Lowe (ed.)Biomolecular Sensors295,99 €
- Philip BegleyMaking Genetics and Genomics Policy in Britain191,99 €
- Abraham Fisher / Maurizio Memo / Fabrizio Stocchi / Israel Hanin (eds.)Advances in Alzheimer's and Parkinson's Disease220,99 €
- Paul S. AgutterAbout Life48,99 €
- Richard Aspinall (ed.)Aging of the Organs and Systems182,99 €
-
-
-
The lungs are the organ for gas exchange between the body and the external environment. This book contributes to the understanding homeostasis of lung cells in the physiological and pathological conditions critical to the development of novel therapeutics.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: CRC Press
- Seitenzahl: 272
- Erscheinungstermin: 20. Februar 2024
- Englisch
- Abmessung: 254mm x 178mm x 18mm
- Gewicht: 721g
- ISBN-13: 9781032409023
- ISBN-10: 1032409029
- Artikelnr.: 69483012
- Verlag: CRC Press
- Seitenzahl: 272
- Erscheinungstermin: 20. Februar 2024
- Englisch
- Abmessung: 254mm x 178mm x 18mm
- Gewicht: 721g
- ISBN-13: 9781032409023
- ISBN-10: 1032409029
- Artikelnr.: 69483012
Yutong Zhao is a Professor of Physiology and Cell Biology at The Ohio State University. He received his clinical medical degree from Dalian Medical University in China and PhD degree from Gifu University School of Medicine in Japan. He was trained in biochemistry, molecular biology, and active lipid signaling during his PhD student period. He joined a pulmonary postdoctoral training program at Johns Hopkins University School of Medicine and received his first NIH R01 funding at the University of Chicago as a Research Assistant Professor. Dr. Zhao is an expert in research fields of lung biology, bioactive lysophospholipid, and protein ubiquitination. His research focuses on investigating the pathogenesis of lung diseases including acute respiratory distress syndrome, pulmonary fibrosis, pulmonary arterial hypertension, asthma, lung cancer, and COPD. The goal of Dr. Zhao's laboratory research is to develop new therapeutic targets for treating lung diseases. Dr. Zhao is active in academic professional services as a reviewer, associate editor, and member of editorial boards of scientific journals and grant review study sections.
Part I: Lung Health and Pulmonary Diseases. Chapter 1. Antimicrobial
Peptides in Lung Health and Pulmonary Diseases. Chapter 2. Alveolar
Epithelium in Lung Injury and Repair. Chapter 3. Environmental Toxicants in
Lung Diseases. Chapter 4. Epigenetic Modifications of Histone in Lung
Fibrosis. Chapter 5. Translational Potential of Hypoxia-inducible factor-2¿
Signaling in Pulmonary Hypertension. Part II: Research Strategies and
Methods in Lung Biology and Pathophysiology. Chapter 6. Utility of Lung
Organoids to Accelerate Our Understanding of Human Pulmonary Development
and Diseases. Chapter 7. Establishment of Animal Models of Pulmonary
Fibrosis. Chapter 8. Research Strategies for Investigating Protein
Ubiquitination in Lung Diseases. Chapter 9. Peroxidative Metabolism of Lung
Lipids in Pulmonary Health and Disease: Emphasis on Methods of Analysis of
Oxidative Modification of Polyunsaturated Membrane Phospholipids. Part III:
Pathogenesis and Therapies of COVID-19. Chapter 10. Renin-Angiotensin
System (RAS) and COVID-19: Exploring the Impact, Inhibition, and Treatment
Strategies. Chapter 11. COVID-19 Therapeutics: Challenges and
Opportunities. Chapter 12. Clinical manifestations and pathogenesis of
COVID-19 pulmonary disease. Part IV: Traditional Chinese Medicine in Lung
Diseases. Chapter 13. Pulmonary Diseases and Traditional Chinese Medicine.
Peptides in Lung Health and Pulmonary Diseases. Chapter 2. Alveolar
Epithelium in Lung Injury and Repair. Chapter 3. Environmental Toxicants in
Lung Diseases. Chapter 4. Epigenetic Modifications of Histone in Lung
Fibrosis. Chapter 5. Translational Potential of Hypoxia-inducible factor-2¿
Signaling in Pulmonary Hypertension. Part II: Research Strategies and
Methods in Lung Biology and Pathophysiology. Chapter 6. Utility of Lung
Organoids to Accelerate Our Understanding of Human Pulmonary Development
and Diseases. Chapter 7. Establishment of Animal Models of Pulmonary
Fibrosis. Chapter 8. Research Strategies for Investigating Protein
Ubiquitination in Lung Diseases. Chapter 9. Peroxidative Metabolism of Lung
Lipids in Pulmonary Health and Disease: Emphasis on Methods of Analysis of
Oxidative Modification of Polyunsaturated Membrane Phospholipids. Part III:
Pathogenesis and Therapies of COVID-19. Chapter 10. Renin-Angiotensin
System (RAS) and COVID-19: Exploring the Impact, Inhibition, and Treatment
Strategies. Chapter 11. COVID-19 Therapeutics: Challenges and
Opportunities. Chapter 12. Clinical manifestations and pathogenesis of
COVID-19 pulmonary disease. Part IV: Traditional Chinese Medicine in Lung
Diseases. Chapter 13. Pulmonary Diseases and Traditional Chinese Medicine.
Part I: Lung Health and Pulmonary Diseases. Chapter 1. Antimicrobial
Peptides in Lung Health and Pulmonary Diseases. Chapter 2. Alveolar
Epithelium in Lung Injury and Repair. Chapter 3. Environmental Toxicants in
Lung Diseases. Chapter 4. Epigenetic Modifications of Histone in Lung
Fibrosis. Chapter 5. Translational Potential of Hypoxia-inducible factor-2¿
Signaling in Pulmonary Hypertension. Part II: Research Strategies and
Methods in Lung Biology and Pathophysiology. Chapter 6. Utility of Lung
Organoids to Accelerate Our Understanding of Human Pulmonary Development
and Diseases. Chapter 7. Establishment of Animal Models of Pulmonary
Fibrosis. Chapter 8. Research Strategies for Investigating Protein
Ubiquitination in Lung Diseases. Chapter 9. Peroxidative Metabolism of Lung
Lipids in Pulmonary Health and Disease: Emphasis on Methods of Analysis of
Oxidative Modification of Polyunsaturated Membrane Phospholipids. Part III:
Pathogenesis and Therapies of COVID-19. Chapter 10. Renin-Angiotensin
System (RAS) and COVID-19: Exploring the Impact, Inhibition, and Treatment
Strategies. Chapter 11. COVID-19 Therapeutics: Challenges and
Opportunities. Chapter 12. Clinical manifestations and pathogenesis of
COVID-19 pulmonary disease. Part IV: Traditional Chinese Medicine in Lung
Diseases. Chapter 13. Pulmonary Diseases and Traditional Chinese Medicine.
Peptides in Lung Health and Pulmonary Diseases. Chapter 2. Alveolar
Epithelium in Lung Injury and Repair. Chapter 3. Environmental Toxicants in
Lung Diseases. Chapter 4. Epigenetic Modifications of Histone in Lung
Fibrosis. Chapter 5. Translational Potential of Hypoxia-inducible factor-2¿
Signaling in Pulmonary Hypertension. Part II: Research Strategies and
Methods in Lung Biology and Pathophysiology. Chapter 6. Utility of Lung
Organoids to Accelerate Our Understanding of Human Pulmonary Development
and Diseases. Chapter 7. Establishment of Animal Models of Pulmonary
Fibrosis. Chapter 8. Research Strategies for Investigating Protein
Ubiquitination in Lung Diseases. Chapter 9. Peroxidative Metabolism of Lung
Lipids in Pulmonary Health and Disease: Emphasis on Methods of Analysis of
Oxidative Modification of Polyunsaturated Membrane Phospholipids. Part III:
Pathogenesis and Therapies of COVID-19. Chapter 10. Renin-Angiotensin
System (RAS) and COVID-19: Exploring the Impact, Inhibition, and Treatment
Strategies. Chapter 11. COVID-19 Therapeutics: Challenges and
Opportunities. Chapter 12. Clinical manifestations and pathogenesis of
COVID-19 pulmonary disease. Part IV: Traditional Chinese Medicine in Lung
Diseases. Chapter 13. Pulmonary Diseases and Traditional Chinese Medicine.